A stimulant medicine with formulation-dependent delivery. ADHD treatment findings and attention-task results should retain their population and exposure context.
Methylphenidate is used in clinical treatment of ADHD and narcolepsy. It inhibits catecholamine reuptake, including dopamine transporters. The displayed structure is the parent compound; study and labeled products commonly contain its hydrochloride salt.
A treatment response in ADHD does not establish cognitive enhancement in people without ADHD.
Assessment belongs to each claim and outcome. An article’s editorial status is not a grade of a substance’s safety or efficacy.Human PET detected dose-dependent transporter occupancy after oral administration. [4]
Descriptions of experience in their reported context. Direction does not imply benefit, and these observations do not define a universal intensity score.
Not assessed. No sourced subjective observations have been curated for this article.
What the research measured, for whom, and under which exposure. Findings remain attached to the study’s task or clinical endpoint.
Attention-task performance improved in the subgroup meeting ADHD diagnostic criteria. Participants without that diagnosis showed a different response pattern. [3]
Published exposure records, distinguished by source category. These describe study or reference context and are not personal dosing recommendations.
30 mg [3]
A monitored experimental exposure, not a dosing recommendation or a formulation conversion.
Absorption, metabolism and elimination depend on the analyte, route, formulation, physiology and other exposures.
Adult immediate-release tablet estimate reported in the Ritalin LA label; formulation controls delivery separately. [2]
The modeled analyte is Methylphenidate. The curve begins after absorption and distribution; it does not predict onset, felt effects, or an individual’s response.
Route: Oral. Formulation: Immediate-release Ritalin tablet. Population: Adults in label pharmacokinetic studies.
Approximate adult mean; distinct from the reported range and from extended-release delivery duration. Source & context
Study mean: 3.5 hours.
The model uses this single study mean; no range is inferred.
Model: fraction remaining = 2−time / half-life. Assumes a single exposure, instantaneous distribution, and a constant half-life for Methylphenidate. Formation of metabolites, repeated exposure, and interactions are not modeled. Source & context
3.5 hoursStudy mean [2]
Approximate adult mean; distinct from the reported range and from extended-release delivery duration.
1.3–7.7 hoursReported range [2]
Reported adult range, not a confidence interval or a personal prediction.
Adverse effects, interactions, tolerance and withdrawal in the cited contexts. This section is not an exhaustive interaction checker.
Prescribing information carries a boxed warning for abuse, misuse and addiction and describes physical dependence and withdrawal. [1]
The label describes cardiovascular and psychiatric risks and monitoring requirements. [1]
Immediate-release elimination data do not describe the release profile of every extended-release product. [2]
The source, the finding and its limitations. Funding information is reported where curated; an unassessed disclosure does not mean a study had no commercial funding.
Describes immediate-release absorption, metabolism, clinical use and safety.
Limitations Formulation-specific labeling; date denotes retrieval, not original approval. It does not establish benefit outside the labeled context.
Funding / disclosures Manufacturer prescribing information hosted by the US National Library of Medicine.
Separately reports adult mean and range for immediate-release methylphenidate elimination.
Limitations Formulation-specific labeling; date denotes retrieval, not original approval. It does not establish benefit outside the labeled context.
Funding / disclosures Manufacturer prescribing information hosted by the US National Library of Medicine.
Observed changes in sustained attention and spatial working memory in the diagnosed subgroup.
Limitations Small acute study, with differing diagnostic subgroups; not evidence for universal enhancement.
Funding / disclosures Not assessed in this draft.
Directly measured dopamine transporter occupancy after oral methylphenidate.
Limitations Small selected sample and a mechanistic endpoint.
Funding / disclosures Not assessed in this draft.
Source of the displayed formula, molecular weight, structure and connectivity SMILES.
Limitations The parent compound identity is distinct from salts, formulations and commercial product quality.
Funding / disclosures US National Library of Medicine.
Each relationship retains its participants, roles and context. Shared membership does not imply that substances should be combined.
Acute exposure in healthy volunteers
Limitation Mechanistic imaging does not measure clinical response.
Evidence strength: not formally assessed.
Not assessed. Absence of a legal record is not a statement of legal status.
This article is a sourced draft. Editorial review has not been recorded. Content date: Sep 29, 2026.